Business
Glycotest Adds Allowed Chinese Patent to Portfolio
Glycotest Adds Allowed Chinese Patent to Portfolio.
About this update from Emv Capital Plc
[{"type":"text","content":"\n \nRNS Number : 3337V NetScientific PLC 02 November 2017 \n\nNetScientific plc\n(\"NetScientific\" or the \"Company\" or the \"Group\")\n \nGlycotest™ Further Strengthens its Intellectual Property Portfolio with an Allowed Chinese Patent \n \nLondon, UK - 02 November 2017 - NetScientific plc (\"NetScientific\", AIM:NSCI), the transatlantic healthcare IP commercialisation Group, announces that a Chinese patent exclusively licensed to one of its portfolio companies, Glycotest, has been allowed. The patent provides broad protection of the assays in Glycotest's HCC Panel test for early-stage hepatocellular carcinoma (HCC) and the Company's pipeline tests for liver fibrosis and other serious liver disease.\n \nThis patent expands Glycotest's existing patent portfolio which has 10 previously granted or allowed patents, protecting multiple aspects of Glycotest's proprietary liver disease diagnostic platform. Glycotest now holds patents in the US, Europe, Japan and Australia covering the use of over 50 unique glycoprotein biomarkers and related assay technology for the diagnosis of liver cancers and other liver diseases. These patents have been licensed exclusively on a worldwide basis to Glycotest by Drexel University College of Medicine and the Blumberg Institute of the Hepatitis B Foundation. \n \nGlycotest's lead product, HCC Panel, has demonstrated in two studies of 208 patients and 127 patients respectively that it has the potential to outperform the current dominant blood test (AFP) regarding the early detection of HCC in patients with cirrhosis.\n \nNetScientific holds an 87.5% stake (67% on a fully diluted basis) in Glycotest. \n \nCommenting on the news, NetScientific's Chief Executive Officer and Chairman of Glycotest, Francois R. Martelet said: \"We are pleased to announce that Glycotest's IP portfolio will now also cover China, a highly significant market, which accounts for over 50% of worldwide deaths from liver cancer. We believe Glycotest's HCC panel will enable early detection of HCC and, once commercialised, will change the paradigm of care.\"\n \nThe full text of the announcement from Glycotest can be found below.\n \nFor more information please contact: \n \nNetScientific \nFrançois R. Martelet, M.D., CEO \nIan Postlethwaite, CFO \nTel: +44 (0)20 3514 1...